Lenient versus strict rate control in patients with atrial fibrillation.

BACKGROUND Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality in patients with permanent atrial fibrillation. METHODS We randomly assigned 614 patients with permanent atrial fibrillation to undergo a lenient rate-control strategy (resting heart rate <110 beats per minute) or a strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute). The primary outcome was a composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events. The duration of follow-up was at least 2 years, with a maximum of 3 years. RESULTS The estimated cumulative incidence of the primary outcome at 3 years was 12.9% in the lenient-control group and 14.9% in the strict-control group, with an absolute difference with respect to the lenient-control group of -2.0 percentage points (90% confidence interval, -7.6 to 3.5; P<0.001 for the prespecified noninferiority margin). The frequencies of the components of the primary outcome were similar in the two groups. More patients in the lenient-control group met the heart-rate target or targets (304 [97.7%], vs. 203 [67.0%] in the strict-control group; P<0.001) with fewer total visits (75 [median, 0], vs. 684 [median, 2]; P<0.001). The frequencies of symptoms and adverse events were similar in the two groups. CONCLUSIONS In patients with permanent atrial fibrillation, lenient rate control is as effective as strict rate control and is easier to achieve. (ClinicalTrials.gov number, NCT00392613.)

[1]  D. J. Veldhuisen,et al.  Presence and development of atrial fibrillation in chronic heart failure , 2006, European journal of heart failure.

[2]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[3]  Elad Anter,et al.  Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic , 2009, Circulation.

[4]  P. Zimetbaum,et al.  Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. , 2006, American heart journal.

[5]  H. Crijns,et al.  Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. , 1993, The American journal of cardiology.

[6]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[7]  S. Hohnloser,et al.  Risk Stratification Using T‐Wave Alternans: More Questions Waiting to be Answered , 2008, Journal of cardiovascular electrophysiology.

[8]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[9]  I. V. Van Gelder,et al.  RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. , 2006, American heart journal.

[10]  B. Olshansky,et al.  Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia , 2004, Circulation.

[11]  PhilippeLechat,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001 .

[12]  J. Dimarco,et al.  Factors Affecting Bleeding Risk During Anticoagulant Therapy in Patients With Atrial Fibrillation: Observations From the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study , 2005 .

[13]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[14]  S. Connolly,et al.  Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter , 2009, Circulation.

[15]  D. Bush,et al.  Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). , 2004, The American journal of cardiology.

[16]  J. Lázzari,et al.  Reversible high rate atrial fibrillation dilated cardiomyopathy. , 1997, Heart.

[17]  I. V. Van Gelder,et al.  A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. , 2006, International journal of cardiology.

[18]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[19]  H. Crijns,et al.  Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[20]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.